LQDA Profile
Liquidia Corporation, headquartered in Morrisville, North Carolina, operates as a biopharmaceutical firm dedicated to addressing unmet patient needs in the United States. Established in 2004, the company focuses on the development, manufacturing, and commercialization of innovative therapeutic products.
Central to Liquidia Corporation's portfolio are its advanced product candidates aimed at tackling significant medical challenges. Among these is YUTREPIA, a notable inhaled dry powder formulation of treprostinil designed specifically for the treatment of pulmonary arterial hypertension (PAH). This innovative treatment approach underscores the company's commitment to enhancing therapeutic outcomes and patient quality of life.
In addition to its proprietary formulations, Liquidia Corporation also plays a critical role in the distribution of generic treprostinil injection across the United States. This dual focus on proprietary development and distribution strengthens the company's market position and diversifies its revenue streams within the biopharmaceutical sector.
With a robust pipeline and a strategic emphasis on therapeutic innovation, Liquidia Corporation continues to advance its mission of delivering impactful healthcare solutions. Through ongoing research and development initiatives and strategic partnerships, the company remains poised to expand its market presence and further establish itself as a leader in addressing complex medical conditions through cutting-edge biopharmaceutical advancements.
|
